A Systematic Review of the Benefit of B-Vitamins as a Complementary Treatment in Cancer Patients

References

• Kennedy DO. B vitamins and the brain: mechanisms, dose and efficacy—a review. Nutrients. 2016;8(2):68. doi:10.3390/nu8020068
   PubMed Web of Science ®Google Scholar
• Davis R, Icke G. Clinical chemistry of thiamin. Adv Clin Chem. 1983;23:93–140.
   PubMed Web of Science ®Google Scholar
• Manzetti S, Zhang J, van der Spoel D. Thiamin function, metabolism, uptake, and transport. Biochemistry. 2014;53(5):821–35. doi:10.1021/bi401618y
   PubMed Web of Science ®Google Scholar
• Sechi G, Sechi E, Fois C, Kumar N. Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults. Nutr Rev. 2016;74(5):281–300. doi:10.1093/nutrit/nuv107
   PubMed Web of Science ®Google Scholar
• Clayton PT. B 6-responsive disorders: a model of vitamin dependency. J Inherit Metab Dis. 2006;29(2-3):317–26. doi:10.1007/s10545-005-0243-2
   PubMed Web of Science ®Google Scholar
• Trakatellis A, Dimitriadou A, Exindari M, Christodoulou D, Malissiovas N, Antoniadis A, Haitoglou K. Effect of combination of deoxypyridoxine with known anti-proliferative or immunosuppressive agents on lymphocyte serine hydroxymethyltransferase. Postgrad Med J. 1994;70(Suppl 1):S89–S92.
   PubMedGoogle Scholar
• Goldsmith GA. Riboflavin deficiency. In: Riboflavin. Boston, MA: Springer; 1975. p. 221–44.
   Google Scholar
• Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149–60. doi:10.1056/NEJMcp1113996
   PubMed Web of Science ®Google Scholar
• Haber PS, Kortt NC. Alcohol use disorder and the gut. Addiction. 2021;116(3):658–67. doi:10.1111/add.15147
   PubMed Web of Science ®Google Scholar
• Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187–203. doi:10.1177/1534735411423920
   PubMed Web of Science ®Google Scholar
• Molassiotis A, Fernández-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005;16(4):655–63. doi:10.1093/annonc/mdi110
   PubMed Web of Science ®Google Scholar
• Ernst E. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer Interdiscip Int J Am Cancer Soc. 1998;83(4):777–82. doi:10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
   Google Scholar
• Nagore E, Insa A, Sanmartín O. Antineoplastic therapy—induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Am J Clin Dermatol. 2000;1(4):225–34. doi:10.2165/00128071-200001040-00004
   PubMedGoogle Scholar
• Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257–71. doi:10.1159/000258880
   PubMed Web of Science ®Google Scholar
• Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006;12(3):131–41. doi:10.1177/1078155206069242
   PubMedGoogle Scholar
• Eifel PJ, Brown DM, Lee WW, Brown JM. Misonidazole neurotoxicity in mice decreased by administration with pyridoxine. Int J Radiat Oncol Biol Phys. 1983;9(10):1513–9. doi:10.1016/0360-3016(83)90326-7
   PubMedGoogle Scholar
• Griffin JW, Price DL, Kuethe DO, Goldberg AM. Neurotoxicity of misonidazole in rats. I. Neuropathology. NeuroToxicology. 1979;1(2):299–312.
   Web of Science ®Google Scholar
• Jackson DV, Pope EK, McMahan RA, Cooper MR, Atkins JN, Callahan RD, Paschold EH, Grimm RA, Hopkins JO, Muss HB, et al. Clinical trial of pyridoxine to reduce vincristine neurotoxicity. J Neurooncol. 1986;4(1):37–41. doi:10.1007/BF02158000
   PubMedGoogle Scholar
• Moore DH, Fowler WC, Jr, Crumpler LS. 5-fluorouracil neurotoxicity. Gynecol Oncol. 1990;36(1):152–4. doi:10.1016/0090-8258(90)90127-7
   PubMed Web of Science ®Google Scholar
• Tavio M, Milan I, Tirelli U. Cancer-related fatigue. Int J Oncol. 2002;21(5):1093–9. doi:10.3892/ijo.21.5.1093
   PubMed Web of Science ®Google Scholar
• Giacalone A, Quitadamo D, Zanet E, Berretta M, Spina M, Tirelli U. Cancer-related fatigue in the elderly. Support Care Cancer. 2013;21(10):2899–911. doi:10.1007/s00520-013-1897-1
   PubMed Web of Science ®Google Scholar
• https://www.sign.ac.uk/checklists-and-notes.html (last accessed October 27, 2020).
   Google Scholar
• German Guideline Program in Oncology (GGPO). https://www.leitlinienprogramm-onkologie.de/english-language/ (last accessed October 27, 2020).
   Google Scholar
• Byar D, Blackard C, Christeson WW. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology. 1977;10(6):556–61. doi:10.1016/0090-4295(77)90101-7
   PubMedGoogle Scholar
• Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol. 1995;27(2):110–6. doi:10.1159/000475139
   PubMedGoogle Scholar
• Ota M, Tatsumi K, Suwa H, Watanabe J, Watanabe K, Osada S, Tanaka K, Shoichi F, Ichikawa Y, Kunisaki C, et al. The effect of pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: a randomized study. Hepatogastroenterology. 2014;61(132):1008–13.
   PubMedGoogle Scholar
• Chalermchai T, Tantiphlachiva K, Suwanrusme H, Voravud N, Sriuranpong V. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. Asia Pac J Clin Oncol. 2010;6(3):155–60. doi:10.1111/j.1743-7563.2010.01311.x
   PubMedGoogle Scholar
• Kang Y-K, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, Ryu M-H, Chang H-M, Lee J-L, Kim TW, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010;28(24):3824–9. doi:10.1200/JCO.2010.29.1807
   PubMed Web of Science ®Google Scholar
• Corrie PG, Bulusu R, Wilson CB, Armstrong G, Bond S, Hardy R, Lao-Sirieix S, Parashar D, Ahmad A, Daniel F, et al. A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. Br J Cancer. 2012;107(4):585–7. doi:10.1038/bjc.2012.318
   PubMedGoogle Scholar
• von Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, Eaton S, Waggoner S. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer. 2010;116(20):4735–43. doi:10.1002/cncr.25262
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang L, Wang Q, Shen J. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review. PLoS One. 2013;8(8):e72245. doi:10.1371/journal.pone.0072245
   PubMedGoogle Scholar
• Braik T, Yim B, Evans AT, Kassem M, Mullane M, Lad T, Hussein L, Cleveland B, McDunn S. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy. J Community Support Oncol. 2014;12(2):65–70. doi:10.12788/jcso.0017
   Google Scholar
• Yap Y-S, Kwok L-L, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S, et al. Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial. JAMA Oncol. 2017;3(11):1538–45. doi:10.1001/jamaoncol.2017.1269
   PubMedGoogle Scholar
• https://www.dge.de/wissenschaft/. (last accessed June 23, 2021).
   Google Scholar
• Mondal S, Choudhury KB, Sharma S, Gupta A, Dutta S. Comparative study among glutamine, acetyl-L-carnitine, vitamin-E and methylcobalamine for treatment of paclitaxel-induced peripheral neuropathy. Clin Cancer Investig J. 2014;3(3):213–9. doi:10.4103/2278-0513.132113
   Google Scholar
• Schloss JM, Colosimo M, Airey C, Masci P, Linnane AW, Vitetta L. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care Cancer. 2017;25(1):195–204. doi:10.1007/s00520-016-3404-y
   PubMedGoogle Scholar
• Gyürgy P, Eckardt RE. Vitamin B 6 and skin lesions in rats. Nature. 1939;144(3646):512– doi:10.1038/144512a0
   Google Scholar
• Vukelja SJ, Lombardo FA, James WD, Weiss RB. Pyroxidine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med. 1989;111(8):688–9. doi:10.7326/0003-4819-111-8-688
   PubMed Web of Science ®Google Scholar
• Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs. 1990;8(1):57–63. doi:10.1007/BF00216925
   PubMedGoogle Scholar
• Scott JM. Folate and vitamin B 12. Proc Nutr Soc. 1999;58(2):441–8. doi:10.1017/s0029665199000580
   PubMed Web of Science ®Google Scholar
• Ostby SA, Smith HJ, Leath CA, III. Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting. Gynecol Oncol Rep. 2019;29:123–5. doi:10.1016/j.gore.2019.07.005
   PubMed Web of Science ®Google Scholar
• Bryan GT, Brown R, Price J. Mouse bladder carcinogenicity of certain tryptophan metabolites and other aromatic nitrogen compounds suspended in cholesterol. Cancer Res. 1964;24(4 Part 1):596–602.
   PubMedGoogle Scholar
• Bryan GT. The role of urinary tryptophan metabolites in the etiology of bladder cancer. Am J Clin Nutr. 1971;24(7):841–7. doi:10.1093/ajcn/24.7.841
   PubMedGoogle Scholar
• Price J, Wear J, Brown R, Satter E, Olson C. Studies on etiology of carcinoma of urinary bladder. J Urol. 1960;83(4):376–82. doi:10.1016/S0022-5347(17)65722-7
   PubMedGoogle Scholar